The Ireland Health Products Regulatory Authority (HPRA) has published a Direct Healthcare Professional Communication from Roche Products (Ireland), in agreement with the European Medicines Agency and the HPRA, advising that tuberculosis (TB; mostly extrapulmonary) has been reported in patients receiving pralsetinib [Gavreto] for the treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer. …
Anzeige
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten